Who Paid My Doc
Lori Laffel
Pediatric Endocrinology Boston, MA Medical Doctor
NPI 1275570228 CMS profile 11987
One Joslin Place, Joslin Diabetes Center, Boston, MA 02215
General payments
$284,975
Research payments
$9,070
Ownership & investment interest
$0
Research they led as principal investigator
$2,959,727
Through program year 2025, Lori Laffel of Boston, MA is reported in the CMS Open Payments database as having received $284,975 across 268 general payments and $9,070 in research payments paid to them. Separately, studies naming them as principal investigator received $2,959,727 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $62,600 | 33 | |
| 2024 | General | $18,415 | 48 | |
| 2023 | General | $29,774 | 47 | |
| 2022 | General | $54,239 | 33 | |
| 2021 | General | $28,071 | 21 | |
| 2020 | General | $39,470 | 23 | |
| 2019 | General | $52,405 | 63 | |
| 2019 | Research | $9,070 | 1 |
Beside peers
- Lori Laffel
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Lori Laffel were reported at $62,600. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Lori Laffel | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $52,405 | $196 | $68–$845 | $163 |
| 2020 | $39,470 | $124 | $37–$722 | $114 |
| 2021 | $28,071 | $134 | $35–$691 | $132 |
| 2022 | $54,239 | $177 | $47–$726 | $149 |
| 2023 | $29,774 | $236 | $75–$887 | $160 |
| 2024 | $18,415 | $259 | $91–$979 | $164 |
| 2025 | $62,600 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
269 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Massachusetts
Joseph Wolfsdorf
Pediatric Endocrinology · Boston, MA
Lynne Levitsky
Pediatric Endocrinology · Boston, MA
Stuart Brink
Pediatric Endocrinology · Waltham, MA
Benjamin Nwosu
Pediatric Endocrinology · Worcester, MA
Amy Seagroves
Pediatric Endocrinology · Boston, MA
Katharine Garvey
Pediatric Endocrinology · Boston, MA
Related records
Pediatric Endocrinology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.